Table 3 Evaluation of the quality of model prediction.

From: Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO

HI-P at Week 16

Predicted Frequencies

Percentage

correct

Cohen’s

Kappa

no

yes

Observed Frequencies

HI-P

N

N

%

 

no

45

0

100.0

0.314

yes

23

9

28.1

Total

%

88.3%

11.7%

70.1%

  1. HI-P Hematologic improvement in platelets.